Overview

Evaluation of ATx201 as a Topical Antibiotic Agent

Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
AntibioTx is developping ATx201 as a topical product for treatment of skin infections, including infected atopic dermatitis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AntibioTx ApS
UNION therapeutics
Treatments:
Anti-Bacterial Agents